Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

In vitro and in vivo cytolethal and antitumor effects of a novel fusion protein targeting IL-24 toward breast cancer cells

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Ali Jahanian-Najafabadi

Citation

Annals of Oncology (2020) 31 (suppl_1): S1-S7. 10.1016/annonc/annonc86

Authors

A. Jahanian-Najafabadi, R. Ghavimi, V. Akbari

Author affiliations

  • Department Of Pharmaceutical Biotechnology, Isfahan University of Medical Sciences and Health Services, 8174673461 - Isfahan/IR
More

Resources

Interleukin-24 (IL-24) is known to selectively induce apoptosis in cancer cells through endoplasmic reticulum (ER) stress when it is expressed inside the cells. However, IL-24 alone is unable to enter the cells and consequently unable to inhibit cell proliferation. In the present study, we developed a novel chimeric protein, P28-IL-24, containing IL-24 which is linked to P-28, a defined cancer specific cell penetrating peptide and a P53 stabilizer, to target IL-24 into breast cancer cells. Afterwards, specific and non-specific cytolethal effect of this fusion protein were evaluated in vitro and in vivo.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings